Dr. Susie Cheng is a Partner at Leason Ellis and a member of the pharma/biotech group. She also chairs the China Practice Group of the firm. Susie focuses on all aspects of U.S. and global strategic patent procurement, licensing and monetization of intellectual property. Her services include due diligence investigation of patent portfolios and products, and involvement in legal proceedings for investment and acquisition opportunities. She also provides inventorship investigation, freedom-to-operate, infringement and patentability opinions. In addition, she provides advice on various agreements, intellectual property disputes and litigation. Her clients operate in a wide range of technologies including biologics, pharmaceuticals, enzyme replacement therapies, cryopreservation, cannabis, biofuels, cosmetics, medical devices, small molecules, nanotechnology, artificial intelligence algorithms in healthcare and biometric authentication. Susie’s clients include academic institutions, start-ups and multinational companies.
Susie loves scientific endeavors and is a strong advocate for individuals and companies in protecting innovative ideas. After finishing her Ph.D. in molecular genetics and post-doc in neuroscience, she attended law school specializing in patent law. For clients doing business in China and those based in China, her fluency in Cantonese and Mandarin Chinese makes her a highly effective advocate. Susie identifies and avoids potential issues that may be raised by the patent office and routinely conducts interviews with Examiners aimed at establishing good rapport, minimizing cost and expediting prosecution. Susie graduated summa cum laude from Hunter College, City University of New York, she obtained her Ph.D. from Columbia University, she was a Post-Doctoral fellow at Rockefeller University, and she received her JD from Brooklyn Law School.